To Kill A Rat: An Antiquated Approach for Finding a Cure - Paperback

by J. C. Spencer (Author)

The FDA requires a rat to die to develop a new drug. You want your doctor to "Do no harm " but the medical battle cry of yesteryear but was lost to toxic drugs. The FDA uses an antiquated LD50 criteria for drug approval. The LD50 standard was established to measure just how harmful is any medicine. Lethal Dose 50 requires that all new drugs must kill 50 percent of the subjects in animal studies. Any medicine that cannot establish a LD50 level is ruled out from any consideration for FDA approval. This single procedure eliminates the non-toxic cures from ever reaching the market. During the last century, the focus has been on problems instead of solutions. The medical industry is focused on resolving the urgent instead the important. The drug establishment knows that the more critical and widespread the problem, the greater the opportunity for profit. The focus remains on sickness instead of wellness. "We need to tear down the barriers blocking a new era of medical innovation, and the primary inhibitor is the government itself. It's past time to unleash a supply-side medical revolution, so that instead of simply caring for people with debilitating diseases, we cure them. ... and embrace a culture of innovation" - Senator Ted Cruz Steve Forbes warned that the FDA's foot-dragging could lead to the death of millions of Americans. He said this FDA mistake could be the "potential catastrophe" of a "bacterial apocalypse." To Kill A Rat applies to what CAN BE in the medical and healthcare field.

Author Biography

JC Spencer has written several Glycoscience books. He has studied the works of over 700 M.D.s, PhDs, Scientists, Researchers, and Educators in the field of Glycoscience and brain function and collaborated with schools, universities, or research labs in thirteen countries. He has enjoyed international adventures and speaking engagements in many countries. Since the 1990s, he has worked closely with several specialists, doctors, and healthcare professionals in Glycoscience which resulted in the publishing of peer-reviewed papers evidencing improved brain function in Alzheimer's patients, and pilot surveys for various neurodegenerative challenges including Alzheimer's, Parkinson's, Huntington's, ALS, Lyme, Autism, and ADHD. He passionately envisions the field of Quantum Glycoscience as the proven bull's eye, the Rosetta Stone, the Holy Grail, of medicine and of all healthcare. JC Spencer is Founder and CEO of the Texas Endowment for Medical Research, Inc, a 501(c)(3) faith-based medical research and education organization and think tank based in Houston, Texas. In collaboration with various organizations, he has conducted surveys on specific biological sugars throughout the United States, Canada, and some foreign countries. He has written extensively about Glycoscience and is also founder and CEO of the Glycoscience Institute. Mr Spencer and his wife, Karen, have four children, ten grandchildren and five great-grandchildren. They live in Houston, Texas. For details on booking the author for lectures at universities and fund raising events, he may be reached at jcs@endowmentmed.org